← All indications
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Subtype terms (8)
More specific conditions that are subtypes of Obesity in the MeSH hierarchy.
- Diabesity
- Obesity, Abdominal
80 drugs (32 approved, 48 experimental)
- Obesity Hypoventilation Syndrome
2 drugs (1 approved, 1 experimental)
- Obesity, Metabolically Benign
4 drugs (2 approved, 2 experimental)
- Obesity, Morbid
99 drugs (80 approved, 19 experimental)
- Pediatric Obesity
68 drugs (33 approved, 35 experimental)
- Prader-Willi Syndrome
33 drugs (17 approved, 16 experimental)
- Pregnancy in Obesity
6 drugs (2 approved, 4 experimental)
Drugs by status
Approved for this indication (36)
- phenmetrazine
- leptin
- diethylpropion hydrochloride
- polyglucosamine
- ephedrine
- stevia
- human choriogonadotropin alfa
- exendin (9-39)
- phendimetrazine
- methamphetamine
- dexfenfluramine
- hydroxycitrate
- lorcaserin
- synthenate
- erythritol
- setmelanotide
- daesiho-tang
- rimonabant
- litramine
- beinaglutide
- fenfluramine
- carob gum
- mazindol
- amphetamine
- benzphetamine
- o-chlorophentermine
- sibutramine
- chlorphentermine
- glucagon-like peptide-1
- pyruvate
- +6 more
Phase 4 trials (183)
- capsicum
- corifollitropin alfa
- lamivudine
- pioglitazone
- sulfamethoxazole
- ethinyl estradiol
- celecoxib
- rocuronium
- mitiglinide
- metformin
- tomato
- liraglutide
- midazolam
- enavogliflozin
- ropivacaine
- folic acid
- dapsone
- vitamin d3
- topiramate
- neostigmine
- empagliflozin
- l-nmma
- emtricitabine
- levobupivacaine
- sodium chloride
- aliskiren
- denatonium benzoate
- somatropin
- erythromycin
- norgestrel
- +153 more
Phase 3 trials (90)
- kisspeptin
- megestrol
- ramipril
- loxenatide
- euiiyin-tang
- felodipine
- trandolapril
- mirikizumab
- ringer's lactate
- resveratrol
- l-epigallocatechin
- tyrosine
- mazdutide
- fisetin
- hrs-7535
- ixekizumab
- zinc dichloride
- l-arabinose
- tea
- propylformic acid
- triticum aestivum pollen
- magnesium
- lactobacillus casei
- magnesium oxide
- bifidobacterium animalis
- inactivated probiotic
- magnesium trisilicate
- hrs9531
- azilsartan
- flax
- +60 more
Phase 2 trials (225)
- thr-4109
- ihbg-10
- xenon-129
- human fecal microbiota
- hdm1005
- tryptophan
- k-757 and k-833
- na-931
- iohexol
- salsalate
- colfosceril palmitate
- ly6249492
- serratiopeptidase
- ro7204239
- danuglipron
- vericiguat
- lb54640
- aphp-002
- chromium
- pp1420
- nattokinase
- ecc5004
- piperine
- nicotine
- imm01
- ly3549492
- s1b-509
- zt002
- isis-fgfr4
- lactobacillus rhamnosus
- +195 more
Phase 1 trials (175)
- bi 3006337
- mango
- blackberry juice
- ceftobiprole
- mitoquinol
- norepinephrine
- zyt1
- omeprazole
- alpelisib
- hrs-5817
- sea grape extract
- rm-718
- acetylcholine chloride
- nesiritide
- telenzepine
- astaxanthin
- azithromycin
- da-1726
- bmf-650
- gma106
- lae102
- avocado
- mk-3655
- nnc0480-0389
- Ecnoglutide
- liver-enriched antimicrobial peptide 2
- phentolamine mesylate
- whey protein
- p7435
- avocadyne
- +145 more
Other trials (356)
- bcad2
- kombucha
- honey
- magnesium citrate
- capecitabine
- isomaltulose
- lipid emulsion
- medium chain triglyceride
- pecan
- apricot
- soybean
- sunflower oil
- nevulose
- cucumber
- alfacalcidol
- beta carotene
- incretin
- iron
- cinnamomum cassia
- dinoprostone
- acai polyphenolics
- eicosapentanoic acid
- clarithromycin
- chromium ethylenediaminetetraacetic acid
- red wine
- glp-1 (7-36) amide
- haloperidol
- phytosterol
- chitosan
- pine nut oil
- +326 more
Organizations
Organization Involved with Phase 4 Indications (103)
- Shire
- Bausch Health Companies
- AstraZeneca
- Merck
- Novo Nordisk
- Vivus
- Novartis
- Allergan
- Cumberland Pharmaceuticals
- Orexigen Therapeutics, Inc
- Daewoong Pharmaceutical Co. LTD.
- European Foundation for the Study of Diabetes
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fundación Cardiovascular de Colombia
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Health Service, United Kingdom
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Funch-Jensen, Peter, M.D., D.M.Sc.
- Goldman, Butterwick, Fitzpatrick and Groff
- Aarhus University
- University of Pittsburgh
- Medical University of Graz
- Baylor University
- University of London
- Chinese Medical Association
- Cornell University
- Harvard University
- Duke University
- +73 more
Organization Involved with Phase 3 Indications (72)
- Eisai
- Eli Lilly
- Pfizer
- Sanofi
- Biopolis S.L.
- Catalysis SL
- GlaxoSmithKline
- Institut Pasteur
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Laboratorios Silanes S.A. de C.V.
- Rhythm Pharmaceuticals, Inc.
- Valbiotis
- Center for Health, Exercise and Sport Sciences, Serbia
- Medical Research Council
- National Institute on Aging (NIA)
- University Hospital, Basel, Switzerland
- Hospital General de México Dr. Eduardo Liceaga
- Augusta University
- Gachon University
- Georgetown University
- University of Washington
- Glaser Pediatric Research Network
- Istituto Auxologico Italiano
- Korea Health Industry Development Institute
- Kyung Hee University
- Kaiser Permanente
- Lithuanian University of Health Sciences
- Postgraduate Institute of Medical Education and Research
- Stanford University
- Thomas Jefferson University
- +42 more
Organization Involved with Phase 2 Indications (95)
- Amylin
- Takeda
- Genentech
- Shionogi
- Athersys, Inc
- Chiesi
- INC Research
- Innovent Biologics (Suzhou) Co. Ltd.
- Ionis Pharmaceuticals, Inc.
- J. Uriach and Company
- Manhattan Pharmaceuticals
- NeuroSearch A/S
- Neothetics, Inc
- Nucitec
- NuSirt Biopharma
- Raziel Therapeutics Ltd.
- Saniona
- Solvay
- Zafgen, Inc.
- vTv Therapeutics
- Genfit
- Theracos
- Fundacion IMIM
- Fundació Sant Joan de Déu
- University of Pennsylvania
- Rockefeller University
- Albany College of Pharmacy and Health Sciences
- American Heart Association
- Case Western Reserve University
- Cindetec
- +65 more
Organization Involved with Phase 1 Indications (25)
- Alizyme
- Bristol-Myers Squibb
- Amgen
- MedImmune
- Bayer
- Kyowa Hakko Kirin
- NGM Biopharmaceuticals, Inc
- Parexel
- Lund University
- New York Chiropractic College
- Oregon Health and Science University
- University of Oklahoma
- University of Turku
- University of Western Brittany
- University of Missouri
- Opko
- University of Oxford
- Pennsylvania State University
- University of Wisconsin
- Susan G. Komen Breast Cancer Foundation
- Government of Finland
- Sigrid Juselius Foundation
- Calo Psychiatric Center
- IDeA States Pediatric Clinical Trials Network
- PharmaNet (2006)
Organization Involved with Other Experimental Indications (127)
- Center for Weight Management, California
- Certmedica International GmbH
- Gateway Health Alliance
- InQpharm Group
- National Institute of General Medical Sciences (NIGMS)
- National Polytechnic Institute, Mexico
- Swiss Federal Institute of Technology
- United States Department of Agriculture
- Shahid Beheshti University of Medical Sciences
- Huazhong University of Science and Technology
- Maastricht University
- University of Manitoba
- Bambino Gesù Hospital and Research Institute
- Centre Hospitalier Universitaire de la Réunion
- China Academy of Chinese Medical Sciences
- Drexel University
- Eskisehir Osmangazi University
- Hiroshima University
- Indiana University
- Instituto Mexicano del Seguro Social
- Instituto Nacional de Cardiologia Ignacio Chavez
- Katholieke Universiteit Leuven
- Johns Hopkins University
- Korea University
- Loma Linda University
- Lovisenberg Diakonale Hospital
- Newcastle University
- Northwestern University
- Regina Qu'Appelle Health Region
- Rio de Janeiro State University
- +97 more